Date | Time | Source | Announcement |
---|---|---|---|
17 Dec 2007 | 07:00 AM | MOU with Swansea University | |
12 Dec 2007 | 11:08 AM | Collaboration Update | |
30 Nov 2007 | 01:54 PM | Holding(s) in Company | |
28 Nov 2007 | 07:00 AM | Final Results - Replacement | |
27 Nov 2007 | 10:33 AM | Final Results | |
24 Sep 2007 | 03:59 PM | Holding(s) in Company | |
17 Sep 2007 | 05:25 PM | Holding(s) in Company | |
17 Sep 2007 | 11:38 AM | Holding(s) in Company | |
17 Sep 2007 | 09:00 AM | Collaboration with Eli Lilly | |
16 Aug 2007 | 07:01 AM | AIM rule 26 information | |
13 Aug 2007 | 02:35 PM | Holding(s) in Company | |
07 Aug 2007 | 04:28 PM | Holding(s) in Company | |
18 May 2007 | 03:53 PM | Directorate Change | |
16 Mar 2007 | 11:15 AM | Interim Results | |
02 Jan 2007 | 07:00 AM | Result of AGM | |
19 Dec 2006 | 01:01 PM | Total Voting Rights | |
07 Dec 2006 | 02:54 PM | Notice of AGM and prelims | |
28 Nov 2006 | 07:01 AM | TEMPO project participation | |
07 Nov 2006 | 04:47 PM | Holding(s) in Company | |
29 Sep 2006 | 02:46 PM | Additional Listing | |
28 Sep 2006 | 12:49 PM | EGM Statement | |
05 Sep 2006 | 02:41 PM | Notice of EGM | |
01 Sep 2006 | 03:25 PM | Board Changes, Placing and Change of Broker | |
08 Jun 2006 | 10:03 AM | Directorate Change | |
28 Apr 2006 | 07:00 AM | Holding(s) in Company | |
31 Mar 2006 | 07:00 AM | Interim Results | |
22 Dec 2005 | 01:04 PM | AGM Statement | |
25 Oct 2005 | 04:02 PM | Statement re: Partial Investing of Share Options | |
18 Oct 2005 | 01:06 PM | Director/PDMR Shareholding | |
08 Sep 2005 | 07:00 AM | Final Results | |
26 Aug 2005 | 07:00 AM | Directorate Change | |
28 Jun 2005 | 11:48 AM | Additional Listing | |
27 Jun 2005 | 07:00 AM | Statement re share subscription and issue of op... | |
23 Jun 2005 | 07:00 AM | Re Agreement | |
21 Mar 2005 | 07:00 AM | Interim Results | |
23 Dec 2004 | 04:54 PM | Registration of UK SystemCell(TM) Patent | |
20 Dec 2004 | 07:00 AM | FIRST DAY OF TRADING ON AIM |
Physiomics plc is a UK-based company that uses mathematical models to help develop cancer treatments and personalized medicine. Services include Virtual Tumor modeling: A combination of proprietary and industry standard technologies that predict the effects of cancer treatments and drugs, Answering R&D questions: Helping clients de-risk drug development and build confidence in a molecule's clinical potential and Predicting therapeutic windows: Helping clients achieve a more quantitative understanding of new molecules.
PYC share price listed at 231p in 2004.